Splash Beverage Acquires Global Rights to CannEpil Therapy
FORT LAUDERDALE, Fla., July 7, 2026 Splash Beverage Group, Inc. has announced the acquisition of exclusive global licensing rights...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
FORT LAUDERDALE, Fla., July 7, 2026 Splash Beverage Group, Inc. has announced the acquisition of exclusive global licensing rights...
NEW YORK, July 7, 2026 The American Parkinson Disease Association (APDA) has announced the launch of “Bridging Mental Health...
April 7, 2026 — Global HeartFocus, developed by DESKi, in partnership with Inteleos®, has launched the first AI-enabled cardiac...
